scholarly journals Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients

2021 ◽  
Vol 15 (10) ◽  
pp. 1489-1496
Author(s):  
Sonia Younas ◽  
Hamid Mukhtar ◽  
Umar Farooq Gohar ◽  
Abdullah Alsrhani ◽  
Badr Alzahrani ◽  
...  
Keyword(s):  
Side Effects ◽  
Molecular Techniques ◽  
Baseline Viral Load ◽  
Hcv Rna ◽  
Efficacy Rate ◽  
Direct Acting Antivirals ◽  
Genotype 3 ◽  
Hcv Genotype ◽  
Hcv Genotype 3 ◽  
Direct Acting

Introduction: The conventional interferon therapy of hepatitis C virus has been substituted substantially with sofosbuvir and daclatasvir due to constraints in efficacy and tolerability. This study aimed diagnostically to monitor the effectiveness and side effects of direct-acting antivirals in the management of HCV infections. Methodology: This prospective study was conducted on HCV-infected patients treated with sofosbuvir and daclatasvir. Different serological, biochemical, hematological, and molecular techniques were used for the assessment of patients. Only treatment-naive patients aged ≥ 18 to 75 years received 12 weeks of treatment. The primary endpoint was a sustained virologic response with undetectable HCV RNA in the patients’ serum at the end of the treatment. Results: We identified 229 cases of confirmed HCV infections by PCR, 94.3% of which had genotype 3. The study population comprised 66% females and 34% males with a median age of 42.2 ± 10.6 SD. Ninety-three percent of the patients accomplished SVR at week 12. The combined therapy of SOF/DAC achieved the highest efficacy rate (92.6%) among the different HCV genotype 3 patients. A statistically significant relationship was observed between low baseline viral load (p < 0.001; 95% CI = 1.2-3.1) and HCV genotype 3 with minor side effects, including lethargy, headache, nausea, insomnia, diarrhea, and fever. Conclusions: HCV-infected patients can be treated well with an interferon-free SOF/DAC regimen, tolerated with generally mild adverse effects with a higher SVR.

Very late relapse in an HCV genotype 3-infected patient treated with direct-acting antivirals (DAA)

2019 ◽  
Vol 75 (1) ◽  
pp. 252-253 ◽  
Author(s):  
Cinzia Caudai ◽  
Chiara Papalini ◽  
Daniela Francisci ◽  
Franco Baldelli ◽  
Maurizio Zazzi
Keyword(s):  
Infected Patient ◽  
Late Relapse ◽  
Direct Acting Antivirals ◽  
Genotype 3 ◽  
Hcv Genotype ◽  
Hcv Genotype 3 ◽  
Direct Acting

Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done

2018 ◽  
Vol 17 (5) ◽  
pp. 0-10
Author(s):  
Susana Llerena ◽  
Joaquín Cabezas ◽  
Antonio Cuadrado ◽  
José Manuel Olmos ◽  
Marta González ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Case Reports ◽  
Rescue Therapy ◽  
Virologic Response ◽  
New Combination ◽  
Direct Acting Antivirals ◽  
Genotype 3 ◽  
Hcv Genotype 3 ◽  
Almost All ◽  
Direct Acting

Nowadays, the retreatment of patients with Hepatitis C virus (HCV) genotype 3 (GT3) especially cirrhotic, who have already been treated with regimens containing a NS5A inhibitor represents a challenge. Use a novel retreatment option for patients with a difficult approach. We present three case reports of retreatment with a new combination of Direct-acting antivirals (DAAs), Sofosbuvir, Elbasvir/ Grazoprevir in patients with GT3 with a previous failure with Sofosbuvir/Ledipasvir. All the cases achieved sustained virologic response (SVR) at week +12 without adverse effects. In our experience, this combo may represent an effective and safe option for these patients.

scholarly journals VIROLOGICAL RESPONSES OF VELPATASVIR/SOFOSBUVIR IN PATIENTS WITH HCV GENOTYPE 3

2020 ◽  
Vol 11 (1) ◽  
pp. 9-14
Author(s):  
Muhammad Sarfraz ◽  
Arshad Rabbani ◽  
Muhammad Shahzad Manzoor ◽  
Benish Adil
Keyword(s):  
Treatment Response ◽  
Sustained Virological Response ◽  
Virological Response ◽  
Hcv Rna ◽  
Rapid Virological Response ◽  
Genotype 3 ◽  
Hcv Genotype ◽  
End Of Treatment ◽  
Treatment Naïve ◽  
Hcv Genotype 3

BACKGROUND & OBJECTIVE: The role of Velpatasvir/Sofosbuvir in the treatment of hepatitis C virus type 3 infection is evaluated in terms of virologic responses. i.e Rapid Virological Response (RVR) End of treatment response (ETR) and Sustained virological response (SVR 12). METHODOLOGY: This was a descriptive case study conducted in Liver OPD of Benazir Bhutto Hospital during 01 November 2018 to 30 April 2019 , in which 100 patients of HCV were enrolled, all of them had HCV genotype 3 infection. Every patient was treated with combination of Velpatasvir/Sofosbuvir 100mg/400 mg Once Daily as part of treatment regimen of HCV infection for 12 weeks. Pre-treatment HCV RNA QUANTITATIVE PCR was done, which was repeated on 4, 12 weeks of treatment and then 12 weeks post treatment. RESULTS: Among 100 patients, 51 (51%) were male and 49 (49%) were females. Mean age of patients was 43.2 ± 10.4 years (mean ± SD). Mean BMI of enrolled patients was 21.34 ± 2.40 kg/m2. 33% patients were cirrhotic while 67% were non cirrhotic. 53% patients were treatment experienced while 47% were treatment naïve. Rapid Virological Response (RVR) was achieved in 92%, End of treatment response (ETR) was achieved in 96%, while Sustained Virological response (SVR12) was achieved in 99% patients. The results were stratified according to age, gender and BMI. There was no effect of these parameters on the final results. CONCLUSION: Virological response (RVR, ETR, SVR12) of Velpatsvir /Sofosbuvir and Ribavirin is encouraging.

scholarly journals HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin

2016 ◽  
Vol 65 (5) ◽  
pp. 1058-1059 ◽  
Author(s):  
Elisabetta Degasperi ◽  
Stella De Nicola ◽  
Mariagrazia Rumi ◽  
Roberta D’Ambrosio
Keyword(s):  
Sustained Virologic Response ◽  
Virologic Response ◽  
Hcv Rna ◽  
Genotype 3 ◽  
Hcv Genotype ◽  
Hcv Genotype 3

scholarly journals Efficacy and safety of sofosbuvir plus ribavirin in treatment-naive chronic hepatitis c genotype 3 patients of South Punjab, Pakistan

2020 ◽  
Vol 8 (12) ◽  
pp. 4242
Author(s):  
Qazi Masroor Ali ◽  
Syed Hashim Raza ◽  
Ali Imran ◽  
Saba Anjum ◽  
Maria Masroor
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Hcv Rna ◽  
Efficacy And Safety ◽  
Genotype 3 ◽  
Hcv Genotype ◽  
End Of Treatment ◽  
Treatment Naïve ◽  
Hcv Genotype 3 ◽  
Chronic Hcv

Background: To evaluate the efficacy and safety of sofosbuvir (SOF) plus ribavirin (RIB) in naive patients with chronic HCV genotype 3. The study design was open label, quasi experimental study. The study was conducted at Medical Outpatient Department of Medical Unit-1, Bahawal Victoria Hospital, affiliated with Quaid e Azam Medical College (QAMC), Bahawalpur, from April 2016 to June 2019.Methods: A total of 627 treatment-naive patients, aged above 18 years, with chronic Hepatitis C virus (HCV) genotype 3 infection were enrolled. SOF as 400 mg once a day plus weight-based RIB (1000 mg/day <75 kg and 1200 mg/day >75 kg) was given to all the study participants for 24 weeks. Qualitative polymerase chain reaction (PCR) for HCV ribonucleic acid (RNA) were done at 4 weeks to note the rapid virological response (RVR) whereas end of treatment response (ETR) was recorded at 24 weeks and sustained virological response (SVR) was noted 3 months after completion of treatment.Results: By 4th week, PCR of 524 (83.6%) patients was available, out of which, 492 (93.9%) had undetectable HCV RNA. By the end of treatment (24 weeks), PCR of 401 (64.0%) patients was available, out of which, 393 (98.0%) had undetectable HCV RNA. Data of 291 (46.4%) patients was available for SVR, 274 (94.1%) had undetectable HCV RNA. Weakness and fatigue turned out to be the commonest side effects, observed in 236 (37.6%) patients.Conclusions: Sofosbuvir was found to have good efficacy and safety in the local population of South Punjab having treatment-naïve chronic HCV genotype 3 infection.

On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir

2016 ◽  
Vol 36 (11) ◽  
pp. 1611-1618 ◽  
Author(s):  
Kris V. Kowdley ◽  
David R. Nelson ◽  
Jacob P. Lalezari ◽  
Terry Box ◽  
Norman Gitlin ◽  
...  
Keyword(s):  
Sustained Virological Response ◽  
Virological Response ◽  
Hcv Rna ◽  
Genotype 3 ◽  
Hcv Genotype ◽  
Hcv Genotype 3
Sign in / Sign up

Export Citation Format

Share Document